Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study aims to assess the technical performance of Tc-99m tetrofosmin SPECT as compared to F-18 FDG PET for the differentiation of radiation necrosis from glioma relapse and to obtain estimates of diagnostic accuracy for Tc-99m tetrofosmin SPECT and F-18 FDG PET in an intra-individual comparison.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05536024` - Combing a Deep Learning-Based Radiomics With Liquid Biopsy for Preoperative and Non-invasive Diagnosis of Glioma

NCT number	NCT02971319
Study type	Interventional
Source	Proactina S.A.
Contact
Status	Completed
Phase	Phase 2
Start date	September 2016
Completion date	December 17, 2017

Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms